KR102407387B1 - 섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법 - Google Patents

섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법 Download PDF

Info

Publication number
KR102407387B1
KR102407387B1 KR1020197003364A KR20197003364A KR102407387B1 KR 102407387 B1 KR102407387 B1 KR 102407387B1 KR 1020197003364 A KR1020197003364 A KR 1020197003364A KR 20197003364 A KR20197003364 A KR 20197003364A KR 102407387 B1 KR102407387 B1 KR 102407387B1
Authority
KR
South Korea
Prior art keywords
fibroblasts
cells
positive
human
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197003364A
Other languages
English (en)
Korean (ko)
Other versions
KR20190117468A (ko
Inventor
타카히로 이와미야
Original Assignee
가부시키가이샤 메토세라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 메토세라 filed Critical 가부시키가이샤 메토세라
Publication of KR20190117468A publication Critical patent/KR20190117468A/ko
Application granted granted Critical
Publication of KR102407387B1 publication Critical patent/KR102407387B1/ko
Assigned to 림포제닉스 리미티드 reassignment 림포제닉스 리미티드 권리의 전부이전등록 Assignors: 가부시키가이샤 메토세라
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197003364A 2017-02-24 2018-02-23 섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법 Active KR102407387B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017033624 2017-02-24
JPJP-P-2017-033624 2017-02-24
PCT/JP2018/006795 WO2018155651A1 (ja) 2017-02-24 2018-02-23 線維芽細胞を含む心臓疾患を治療するための注射用組成物、及び治療用線維芽細胞の製造方法

Publications (2)

Publication Number Publication Date
KR20190117468A KR20190117468A (ko) 2019-10-16
KR102407387B1 true KR102407387B1 (ko) 2022-06-10

Family

ID=63253929

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197003364A Active KR102407387B1 (ko) 2017-02-24 2018-02-23 섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법

Country Status (12)

Country Link
US (2) US11096969B2 (OSRAM)
EP (1) EP3476395B1 (OSRAM)
JP (2) JP6618066B2 (OSRAM)
KR (1) KR102407387B1 (OSRAM)
CN (1) CN109890398B (OSRAM)
AU (1) AU2018223739B2 (OSRAM)
CA (1) CA3032654A1 (OSRAM)
DK (1) DK3476395T3 (OSRAM)
ES (1) ES2885080T3 (OSRAM)
IL (1) IL267958B2 (OSRAM)
SG (1) SG11201900810WA (OSRAM)
WO (1) WO2018155651A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL281081B (en) 2018-08-29 2022-07-01 Metcela Inc A method to generate fibroblast and fibroblastic mass positive for g-csf
CN109589337B (zh) 2018-12-29 2022-04-26 南京艾尔普再生医学科技有限公司 心肌细胞制剂及其制备方法和应用
CN115210361B (zh) * 2020-03-04 2024-12-10 淋巴奥格尼克斯有限公司 促红细胞生成素产生能力增强的成纤维细胞、制造方法以及医药组合物
IL305069A (en) * 2021-03-04 2023-10-01 Metcela Inc Fibroblast beta-factor promotes lymphangiogenesis, and a pharmaceutical preparation containing it
JPWO2023037868A1 (OSRAM) * 2021-09-08 2023-03-16
EP4249585A1 (en) * 2022-03-25 2023-09-27 Technische Universität München - TUM Heart tissue models, method of producing heart tissue models and uses of heart tissue models

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
JP2005524496A (ja) * 2002-05-08 2005-08-18 ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア 非破壊性心伝導ブロック形成用システム及び方法
JP2005538945A (ja) * 2002-05-08 2005-12-22 ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア 心不整脈を線維芽細胞で治療するためのシステム及び方法
US20040161412A1 (en) * 2002-08-22 2004-08-19 The Cleveland Clinic Foundation Cell-based VEGF delivery
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
EP1689284A4 (en) * 2003-11-10 2010-03-17 Symphony Medical Inc METHOD FOR REGULATING VENTRICULAR RHYTHM IN AURICULAR FIBRILLATION PATIENTS
US8513011B2 (en) * 2004-08-26 2013-08-20 Biotech Research Ventures Pte Limited Methods and compositions for culturing cardiomyocyte-like cells
ES2325715B1 (es) * 2007-08-03 2010-06-17 Genetrix, S.L. Poblacion de celulas madre adultas derivadas de tejido adiposo cardiaco y su uso en regeneracion cardiaca.
JP5378743B2 (ja) 2008-09-30 2013-12-25 テルモ株式会社 医療用細胞シートの製造方法
US8802144B2 (en) * 2011-08-25 2014-08-12 Wisconsin Alumni Research Foundation 3-dimensional cardiac fibroblast derived extracellular matrix
JP5920741B2 (ja) 2012-03-15 2016-05-18 ｉＨｅａｒｔ Ｊａｐａｎ株式会社 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法
WO2014039995A1 (en) * 2012-09-07 2014-03-13 Fibrocell Technologies, Inc. Fibroblast compositions for treating cardial damage after an infarct
GB201309057D0 (en) 2013-05-20 2013-07-03 Cell Therapy Ltd Method
KR20150009655A (ko) * 2013-07-16 2015-01-27 학교법인 동아학숙 Gcp-2 유전자를 과발현하는 지방 간엽줄기세포를 포함하는 허혈성 질환 치료용 조성물
CN106661552B (zh) * 2014-07-11 2020-07-07 玛土撤拉有限公司 心脏细胞培养材料

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
비특허문헌

Also Published As

Publication number Publication date
CA3032654A1 (en) 2018-08-30
JP2019218408A (ja) 2019-12-26
CN109890398B (zh) 2024-01-16
EP3476395A4 (en) 2020-02-26
IL267958B1 (en) 2023-04-01
JPWO2018155651A1 (ja) 2019-11-07
KR20190117468A (ko) 2019-10-16
EP3476395A1 (en) 2019-05-01
EP3476395B1 (en) 2021-07-21
JP6618066B2 (ja) 2019-12-11
SG11201900810WA (en) 2019-02-27
AU2018223739A1 (en) 2019-02-14
US11096969B2 (en) 2021-08-24
CN109890398A (zh) 2019-06-14
ES2885080T3 (es) 2021-12-13
US20190224250A1 (en) 2019-07-25
IL267958B2 (en) 2023-08-01
AU2018223739B2 (en) 2023-06-22
US20210346436A1 (en) 2021-11-11
DK3476395T3 (da) 2021-08-16
JP7072135B2 (ja) 2022-05-20
IL267958A (en) 2019-09-26
WO2018155651A1 (ja) 2018-08-30

Similar Documents

Publication Publication Date Title
US11096969B2 (en) Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use
Bao et al. C-Kit Positive cardiac stem cells and bone marrow–derived mesenchymal stem cells synergistically enhance angiogenesis and improve cardiac function after myocardial infarction in a paracrine manner
JP7528149B2 (ja) 心不全の治療方法
US20200085875A1 (en) Platelet vesicle-engineered cells for targeted tissue repair
JP7428389B2 (ja) 線維芽細胞の製造方法及びｇ－ｃｓｆ陽性線維芽細胞集団
CN108472319A (zh) 用于治疗心脏病的移植材料
US20160346331A1 (en) Cardiac tissue-derived cells
Yannarelli et al. Donor mesenchymal stromal cells (MSCs) undergo variable cardiac reprogramming in vivo and predominantly co-express cardiac and stromal determinants after experimental acute myocardial infarction
Fatkhudinov et al. Bone Marrow‐Derived Multipotent Stromal Cells Promote Myocardial Fibrosis and Reverse Remodeling of the Left Ventricle
JP2018530992A (ja) 間葉系幹細胞、そのクローン原性増殖方法、分離方法及び用途
CN108486046B (zh) 一种抗缺氧损伤的干细胞制剂及其制备方法与在制备治疗急性心梗药物中的应用
EP2205251A1 (en) A method to amplify cardiac stem cells in vitro and in vivo
WO2024176514A1 (ja) 心臓内幹細胞を含む細胞集団
US20160166617A1 (en) Macromolecular clusters of cardiac stem cells and methods for making and using them

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5